Miki Aihara

671 total citations
16 papers, 571 citations indexed

About

Miki Aihara is a scholar working on Surgery, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Miki Aihara has authored 16 papers receiving a total of 571 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Surgery, 5 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Miki Aihara's work include Helicobacter pylori-related gastroenterology studies (4 papers), Organ Donation and Transplantation (2 papers) and Renal and related cancers (2 papers). Miki Aihara is often cited by papers focused on Helicobacter pylori-related gastroenterology studies (4 papers), Organ Donation and Transplantation (2 papers) and Renal and related cancers (2 papers). Miki Aihara collaborates with scholars based in Japan, Spain and Netherlands. Miki Aihara's co-authors include Mikio Kikuchi, Yasukazu Ohmoto, K Imagawa, Hisao Takizawa, Daisuke Tsuchimoto, Atsushi Azuma, Naofumi Mukaida, Koji Matsushima, H Wakebe and Yohei Funakoshi and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Antimicrobial Agents and Chemotherapy and Infection and Immunity.

In The Last Decade

Miki Aihara

15 papers receiving 552 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Miki Aihara Japan 9 310 201 115 92 75 16 571
Fukuto Maruta Japan 14 435 1.4× 114 0.6× 171 1.5× 92 1.0× 96 1.3× 31 661
Naoki Sawai Japan 12 407 1.3× 299 1.5× 108 0.9× 109 1.2× 55 0.7× 24 618
Canxia Xu China 14 310 1.0× 204 1.0× 215 1.9× 30 0.3× 57 0.8× 56 622
Kathleen S. Cormier United States 6 150 0.5× 140 0.7× 140 1.2× 40 0.4× 108 1.4× 7 452
Chi‐Tan Hu Taiwan 18 192 0.6× 92 0.5× 303 2.6× 58 0.6× 79 1.1× 48 823
Antonia R. Sepulveda United States 9 187 0.6× 35 0.2× 126 1.1× 85 0.9× 43 0.6× 10 424
Weon Seon Hong South Korea 9 166 0.5× 91 0.5× 145 1.3× 16 0.2× 84 1.1× 30 425
Nobumi Suzuki Japan 16 311 1.0× 127 0.6× 303 2.6× 18 0.2× 216 2.9× 49 806
Radosław Kempiński Poland 13 147 0.5× 72 0.4× 103 0.9× 24 0.3× 44 0.6× 34 461
Luís Pedro Afonso Portugal 19 281 0.9× 212 1.1× 281 2.4× 74 0.8× 307 4.1× 41 994

Countries citing papers authored by Miki Aihara

Since Specialization
Citations

This map shows the geographic impact of Miki Aihara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miki Aihara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miki Aihara more than expected).

Fields of papers citing papers by Miki Aihara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miki Aihara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miki Aihara. The network helps show where Miki Aihara may publish in the future.

Co-authorship network of co-authors of Miki Aihara

This figure shows the co-authorship network connecting the top 25 collaborators of Miki Aihara. A scholar is included among the top collaborators of Miki Aihara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miki Aihara. Miki Aihara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Yamada, Yoshihisa, Hiroyuki Fujiki, Hiroshi Mizuguchi, et al.. (2022). Tolvaptan, a vasopressin V<sub>2</sub> receptor antagonist, is the world’s first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD). Folia Pharmacologica Japonica. 157(4). 254–260.
3.
Yamada, Yoshihisa, Hiroyuki Fujiki, Hiroshi Mizuguchi, et al.. (2021). Tolvaptan, a vasopressin V<sub>2</sub> receptor antagonist, is the world’s first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD). Proceedings for Annual Meeting of The Japanese Pharmacological Society. 94(0). 1–S11. 1 indexed citations
4.
Aihara, Miki, Hiroyuki Fujiki, Hiroshi Mizuguchi, et al.. (2014). Tolvaptan Delays the Onset of End-Stage Renal Disease in a Polycystic Kidney Disease Model by Suppressing Increases in Kidney Volume and Renal Injury. Journal of Pharmacology and Experimental Therapeutics. 349(2). 258–267. 52 indexed citations
5.
Hattori, Katsuji, Takahiro Hirano, Kenji Uehara, et al.. (2010). Functional and Structural Changes in End-Stage Kidney Disease due to Glomerulonephritis Induced by the Recombinant .ALPHA.3(IV)NC1 Domain. EXPERIMENTAL ANIMALS. 59(2). 157–170. 7 indexed citations
6.
7.
Kitadai, Yasuhiko, Atsunori Sasaki, Masanori Ito, et al.. (2003). Helicobacter pylori infection influences expression of genes related to angiogenesis and invasion in human gastric carcinoma cells. Biochemical and Biophysical Research Communications. 311(4). 809–814. 73 indexed citations
8.
Ishidoh, Kazumi, Mitsue Takeda‐Ezaki, Shinya Watanabe, et al.. (1999). Analysis of Where and Which Types of Proteinases Participate in Lysosomal Proteinase Processing Using Bafilomycin Al and Helicobacter pylori Vac A Toxin. The Journal of Biochemistry. 125(4). 770–779. 34 indexed citations
9.
Aihara, Miki, Atsushi Azuma, Hisao Takizawa, et al.. (1998). Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines.. PubMed. 43(9 Suppl). 174S–180S. 42 indexed citations
10.
Hayashi, Shunji, Toshiro Sugiyama, Hiroshi Isogai, et al.. (1998). Effect of Rebamipide, a Novel Antiulcer Agent, on Helicobacter pylori Adhesion to Gastric Epithelial Cells. Antimicrobial Agents and Chemotherapy. 42(8). 1895–1899. 43 indexed citations
11.
Aihara, Miki, K Imagawa, Yohei Funakoshi, Yasukazu Ohmoto, & Mikio Kikuchi. (1998). Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells.. PubMed. 43(9 Suppl). 160S–166S. 56 indexed citations
12.
Tsuchihashi, Kenji, Katsumi Iizuka, Miki Aihara, et al.. (1997). [Vitamin D3 induction of differentiation of HL-60 cells to monocyte- like cells and their aggregation--a dynamic culture method and clarithromycin].. PubMed. 50 Suppl A. 125–6. 1 indexed citations
13.
Aihara, Miki, Daisuke Tsuchimoto, Hisao Takizawa, et al.. (1997). Mechanisms involved in Helicobacter pylori-induced interleukin-8 production by a gastric cancer cell line, MKN45. Infection and Immunity. 65(8). 3218–3224. 224 indexed citations
14.
Aihara, Miki, Masafumi Shibamori, Kenichi Imagawa, et al.. (1992). In vitro Anti‐tumor Activity of Anti‐c‐erbB‐2 × Anti‐CD3ɛ Bifunctional Monoclonal Antibody. Japanese Journal of Cancer Research. 83(6). 563–567. 5 indexed citations
15.
Schmidt‐Wolf, Ingo, et al.. (1992). In vitro and in vivo activity of murine lymphokine‐activated killer cells after cryopreservation. Transfusion. 32(1). 42–45. 10 indexed citations
16.
Sawada, Yoshiaki, et al.. (1991). [Orthostatic purpura: report of two cases].. PubMed. 32(12). 1569–73. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fukuto Maruta Breakdown of academic impact, for papers by Naoki Sawai Breakdown of academic impact, for papers by Canxia Xu Breakdown of academic impact, for papers by Kathleen S. Cormier Breakdown of academic impact, for papers by Chi‐Tan Hu Breakdown of academic impact, for papers by Antonia R. Sepulveda Breakdown of academic impact, for papers by Weon Seon Hong Breakdown of academic impact, for papers by Nobumi Suzuki Breakdown of academic impact, for papers by Radosław Kempiński Breakdown of academic impact, for papers by Luís Pedro Afonso
Rankless by CCL
2026